India Sets Pharma Export Growth Targets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

India Sets Pharma Export Growth Targets



Untitled Document India Brand Equity Foundation (IBEF) and Pharmexcil reported at CPhI Worldwide the country’s plans for growth and its commitment to lowering the cost of medicines globally. In 2012, India was recognized by UNICEF’s Supply Annual Report as the largest supplier of generics globally.

This year India’s pharma exports stands at $14.7 billion (2012-2013), registering a growth rate of 11%, with 55% of exports heading to highly regulated western markets. India is working to improve access to life-saving medicines in developing economies and the government has set a target of $25 billion for pharmaceutical exports by 2016.

The government of India has made tax breaks available to the pharmaceutical sector and a weighted tax deduction of 150% for any R&D expenditure incurred. They have also introduced 19 special economic zones to help stimulate pharma sector investment across the country. As a result of these initiatives, it is predicted that R&D expenditure will continue to grow at an annualized rate of nearly 20% for the next few years. In addition, the Department of Pharmaceuticals has set aside $478.4 million to set up 10 more National Institute of Pharmaceutical Education and Research (NIPER).

Source: India Brand Equity Foundation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here